Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
2 studies found for:    22995650 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Active, not recruiting Aprepitant vs. Desloratadine in EGFR-TKIs Related Pruritus Treatment
Condition: Non-small Cell Lung Cancer
Interventions: Drug: Aprepitant and placebo;   Drug: desloratadine and placebo
2 Completed Aprepitant in the Management of Biological Therapies-related Severe Pruritus
Condition: ITCH
Interventions: Drug: Aprepitant;   Drug: Prednisone;   Drug: Fexofenadine

Indicates status has not been verified in more than two years